Infinity Pharmaceuticals Inc.
780 Memorial Drive
About Infinity Pharmaceuticals Inc.The mission of Infinity Pharmaceuticals, Inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation.
Small molecule discovery and development capabilities Infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation.
Strategic alliances Building on its strengths in innovative small molecule drug discovery and development, Infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline.
Business and scientific expertise The company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business and drug discovery and development.
Culture of Citizen-Ownership Infinity’s culture and environment of Citizen-Ownership is as important as its technologies. Infinity works together as a community with the shared goal of bringing important new medicines to patients.
369 articles with Infinity Pharmaceuticals Inc.
BMS Clinical Collaboration on MARIO-275, a Randomized Study of IPI-549 and Opdivo® (nivolumab) in I/O Naïve Urothelial Cancer to be Initiated in 2Q19
Infinity To Initiate MARIO-3, A Phase 2 Multi-Arm Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer
MARIO-3 Will Evaluate IPI-549 with Tecentriq and Abraxane® in Front-Line Triple Negative Breast Cancer and IPI-549 with Tecentriq and Avastin® in Front-Line Renal Cell Cancer
Infinity Pharmaceuticals, Inc. will host a conference call on Thursday, March 14, 2019, at 8:00 a.m. ET to review its full year 2018 financial results and provide an update on the company.
Infinity Retains $22.5 Million in Gross Proceeds After Sharing with Takeda
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Infinity Pharmaceutical's Chief Executive Officer, will present at the BIO CEO & Investor Conference on Monday, February 11, 2019, at 10:00 a.m. EST at The New York Marriott Marquis in New York, NY
IPI-549 Safety and Clinical Activity Support Initiation of Studies in Earlier Lines of Cancer Therapy with Double and Triple Combination Regimens
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) will be presenting at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019, at 9:30 a.m. PST (12:30 p.m. EST) in San Francisco, CA.
Toward the end of every year, biopharma executives are asked to dust off their crystal balls and predict what the next year might reveal. It’s that time of year again! Find out what execs are saying about M&A, gene therapy, sickle cell, and more.
Infinity Reports Clinical and Translational Data from Expansion Cohorts of MARIO‑1 Phase 1b Study of IPI-549 in Combination with Opdivo® (nivolumab) at SITC's 33rd Annual Meeting
Clinical Activity and Translational Data from IPI-549 in Monotherapy and in Combination with Opdivo Support On-Mechanism Proof of Concept
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H'19
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2018 financial results and provided an update on the company and its progress with IPI-549, a first-in-class oral immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase-gamma
Combination Expansion Data from the IPI-549 MARIO-1 Phase 1b Study to be Presented
Infinity Pharmaceuticals, Inc. will host a conference call on Monday, November 5, 2018, at 4:30 p.m. ET to review its third quarter 2018 financial results
For those looking for work, it’s good to know that some positions are in such demand that employers are falling all over themselves to offer hiring incentives. That’s the case with the biotech sector in Massachusetts, as many companies are dangling almost unheard-of benefits as incentives.
A live webcast of the presentation will be available on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.
Infinity Pharmaceuticals Earns $22 Million Payment From Verastem Oncology For FDA Approval Of COPIKTRA™ (duvelisib) And Updates 2018 Financial Guidance
Infinity Pharmaceuticals, Inc. announced today that it earned a $22 million payment from Verastem Oncology under the license agreement between the Company and Verastem for COPIKTRA (duvelisib).
In the news release, Infinity To Present At Cantor Fitzgerald Global Healthcare Conference, issued 26-Sep-2018 by Infinity Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the presentation date and time for the Cantor Fitzgerald Global Healthcare Conference have been updated. The complete, corrected release follows:
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at Cantor Fitzgerald's Global Healthcare Conference on Wednesday, October 3, 2018, at 5:10 p.m. ET at the Intercontinental New York Barclay Hotel in New York, NY.
9/25/2018Shares of Verastem closed out Monday trading on a positive note and continues to climb in the premarket following the greenlight for leukemia drug Copiktra, an inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma.
A live webcast of the presentation for each of these conferences, excluding the BioCentury NewsMakers lunch panel discussion, will be available on the Investors/Media section of Infinity's website